Synergistic stimulation of mucociliary clearance to treat mucosal obstruction in cystic fibrosis and other muco-obstructive disorders

AR135561A1Pending Publication Date: 2026-09-30THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

0 Cites 0 Cited by

Patent Information

Application Number: ARP20250100793
Authority / Receiving Office: AR · AR
Patent Type: Applications
Current Assignee / Owner
Filing Date: 2025-03-26
Publication Date: 2026-09-30

Application Information

Patent Timeline

26 Mar 2025

Application

ARP20250100793

30 Sep 2026

Publication

AR135561A1

IPC: A61K31/00; A61K45/06; A61K31/44; A61K31/41; A61K31/52; A61P11/00; A61P11/06; A61P11/04

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

No text content released.

Claims

This disclosure provides methods for treating an individual for a muco-obstructive disorder, wherein the methods include: administering to the individual a β-adrenergic agonist or an adenylate cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.

1. A method for treating an individual for a muco-obstructive disorder, characterized in that the method comprises: administering to the individual a β-adrenergic agonist or an adenylyl cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.

18. A pharmaceutical composition characterized in that it comprises: a β-adrenergic agonist or an adenylyl cyclase activator; a cholinergic agonist; and a pharmaceutical excipient.